- Home
- BEAM
as 12-20-2024 4:00pm EST
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.9B | IPO Year: | 2020 |
| Target Price: | $47.67 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.84 - $49.50 | Next Earning Date: | 11-05-2024 |
| Revenue: | $349,643,000 | Revenue Growth: | 328.73% |
| Revenue Growth (this year): | -86.27% | Revenue Growth (next year): | 10.82% |
Stock Insider Trading Activity of Beam Therapeutics Inc. (BEAM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ciaramella Giuseppe | BEAM | President | Nov 6 '24 | Sell | $26.36 | 51,110 | $1,347,050.05 | 109,150 | |
| Ciaramella Giuseppe | BEAM | President | Oct 14 '24 | Sell | $26.27 | 51,110 | $1,342,751.70 | 109,150 | |
| Bellon Christine | BEAM | Chief Legal Officer | Oct 1 '24 | Sell | $23.48 | 385 | $9,039.57 | 104,209 | |
| Evans John M. | BEAM | CEO | Sep 30 '24 | Sell | $24.60 | 60,000 | $1,476,024.00 | 938,659 | |
| Cavanagh Bethany J | BEAM | SVP, Finance and Treasurer | Sep 30 '24 | Sell | $23.48 | 289 | $6,785.46 | 44,931 |
Latest Beam Therapeutics Inc. News
BEAM Breaking Stock News: Dive into BEAM Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Insider Monkey
11 days ago
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers
Benzinga
13 days ago
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
Zacks
14 days ago
Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up
BioPharma Dive
14 days ago
ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug
MT Newswires
14 days ago
Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment
GlobeNewswire
14 days ago
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire
15 days ago
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
Compare BEAM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BEAM Beam Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.